Esophagitis: Reflux PPI Response, Eosinophilic Findings Basics & Alarm Dysphagia

Esophagitis describes inflammation of the squamous mucosa lining the esophagus, with cellular and macroscopic patterns that vary by cause. The dominant adult phenotype—reflux esophagitis—results from chronic exposure of the distal mucosa to gastric acid and pepsin, often with bile reflux, against a background of incompetent lower esophageal sphincter tone, transient sphincter relaxations or impaired esophageal clearance. Tight-fitting hiatal hernias, obesity, pregnancy and delayed gastric emptying compound exposure time.

Eosinophilic esophagitis is a chronic, type 2–driven, food and aeroallergen-modulated disease in which eosinophil-rich infiltrates produce rings, longitudinal furrows, white exudates, edema and progressive fibrosis with strictures. Infectious esophagitis—predominantly Candida, herpes simplex virus and cytomegalovirus—occurs when host defenses falter, including poorly controlled HIV, transplant immunosuppression, prolonged corticosteroid or biologic use, hematologic malignancy on cytotoxic therapy, and sometimes inhaled-steroid users with poor mouth-rinse practice. Pill esophagitis is a focal chemical injury caused by tablets that adhere to the mucosa—classically bisphosphonates, doxycycline and other tetracyclines, NSAIDs, potassium chloride, iron salts and quinidine—particularly when swallowed without adequate water, supine or near bedtime.

Clinicians stratify management against phenotype, severity, comorbidity burden and complication risk. Acute hospital encounters typically focus on bleeding control, food-bolus retrieval, sepsis vigilance in immunocompromised hosts and safe oral-medication review, while ambulatory work centers on sustained acid suppression, eosinophilic-disease control and stricture prevention.

Severity language is endoscopy-driven for reflux disease and biopsy-driven for eosinophilic disease. The Los Angeles (LA) system grades mucosal breaks visually, while the Eosinophilic Esophagitis Endoscopic Reference Score (EREFS)—edema, rings, exudates, furrows, strictures—captures eosinophilic findings semi-quantitatively. Nurses do not stage disease independently, yet recognising the grading vocabulary supports accurate handoffs, anticipation of repeat scopes and counselling on long-term acid suppression versus dietary therapy.

↔On a small screen, swipe or scroll sideways to see the full table.

Severity drift between scopes—particularly worsening from grade A/B to C/D despite therapy—signals adherence failure, alternative phenotype or contributing pathology and warrants documented escalation rather than passive dose increases.

Presentation overlaps across phenotypes; symptom timing, food triggers and host immune status help triangulate the underlying mechanism.

Typical features

• Heartburn—retrosternal burning, worse postprandially or supine, classically responsive to acid suppression in reflux disease.
• Regurgitation of acidic or bitter material, particularly after large or fatty meals.
• Retrosternal chest pain that may mimic cardiac ischaemia—exclude cardiac causes before attributing to esophagitis in middle-aged or higher-risk adults.
• Epigastric or upper abdominal discomfort, sometimes labelled “indigestion” by patients.
• Odynophagia—painful swallowing—particularly suggestive of infectious or pill-induced injury.

Atypical or phenotype-suggesting patterns

• Solid-food dysphagia, food impaction or “slow eating” rituals in younger atopic adults raise eosinophilic disease suspicion even without classic heartburn.
• Hoarseness, throat clearing, chronic cough, dental erosion or laryngitis-like complaints support extra-esophageal reflux—corroborate with timing rather than assuming.
• Persistent nausea, vomiting or post-prandial fullness with weight loss should never be reflexively attributed to “just reflux”—imaging and endoscopy reassessments matter.
• Frail elders, patients on steroids, biologics or chemotherapy may have muted pyrexia and pain responses while harbouring infectious or perforated disease.

Risk profiling shapes investigations more than any single laboratory test. Reflux esophagitis is driven by transient lower esophageal sphincter relaxations, hiatal hernia, central obesity, smoking, pregnancy, prolonged supine posture and—pharmacologically—calcium-channel blockers, nitrates, anticholinergics and theophylline that lower sphincter pressure. Peptic ulcer and gastritis commonly coexist and influence acid-suppression decisions.

Eosinophilic esophagitis disproportionately affects young to middle-aged males with personal or family history of food allergy, eczema, allergic rhinitis or asthma. Infectious esophagitis clusters in immunocompromised cohorts—untreated HIV, solid-organ or stem-cell transplant, prolonged corticosteroid or biologic therapy, hematologic malignancy and poorly controlled diabetes—and may complicate inhaled-steroid use without consistent mouth-rinse practice; oral thrush on inspection raises Candida esophageal involvement substantially.

Pill esophagitis emerges where tablets spend prolonged contact time with the mucosa—oral bisphosphonates, doxycycline and other tetracyclines, potassium chloride preparations, NSAIDs, iron salts, quinidine and ascorbic acid all feature in case series, particularly when swallowed with little water, in the supine position or just before sleep. Radiation, caustic ingestion, prior endoscopic therapy and motility disorders such as achalasia contribute additional, less common pathways.

Clinical assessment

Take a structured history covering symptom timing, dietary triggers, pill burden and exact administration habits, atopic comorbidity, immunosuppression status and prior endoscopic results. Perform a focused abdominal examination, inspect the oropharynx for thrush, document weight trajectory and capture pain features—site, radiation, severity, modifiers—using a structured pain assessment framework.

Laboratory investigations

• Full blood count for occult anemia signaling chronic mucosal blood loss.
• Comprehensive metabolic panel for renal, hepatic and electrolyte baselines before initiating high-dose acid suppression or systemic antifungals.
• Helicobacter pylori testing when peptic ulcer disease is plausible—test-and-treat strategies influence long-term acid suppression decisions.
• HIV testing, CD4 count, blood cultures and fungal/viral PCR work as guided by phenotype and immune status.

Imaging and endoscopy

Upper endoscopy with biopsies remains the diagnostic anchor and is mandatory when alarm features are present. Targeted biopsies—two to four from the distal and two to four from the mid/proximal esophagus—are essential for eosinophilic esophagitis confirmation (≥15 eosinophils per high-power field) and to identify viral inclusions or fungal pseudohyphae in suspected infection. Brushings increase Candida yield. Barium swallow and esophageal manometry have niche roles in dysmotility or stricture mapping. Cross-sectional imaging is reserved for suspected perforation, abscess or extra-luminal complications.

Diagnostic criteria / scoring systems

Reflux disease severity uses the LA classification at endoscopy; eosinophilic disease relies on the AGREE consensus criteria pairing clinical symptoms with histologic eosinophil thresholds after exclusion of competing causes; reflux questionnaires (e.g. GerdQ) support primary-care triage but never substitute for endoscopy when alarms are present.

↔On a small screen, swipe or scroll sideways to see the full table.

First-line management by phenotype

• Reflux esophagitis: Once-daily proton pump inhibitor 30–60 minutes pre-meal for 4–8 weeks—examples include omeprazole, esomeprazole or pantoprazole; LA grade C/D usually requires twice-daily dosing and longer maintenance courses.
• H2-receptor antagonists (e.g. famotidine): Useful for nocturnal acid breakthrough, intolerance to PPIs or step-down therapy; alginate-based products provide adjunctive symptom relief.
• Mucosal protectants: Sucralfate can support symptomatic relief in pill-induced or radiation injury—avoid concurrent administration with other oral drugs to prevent binding interactions.
• Eosinophilic esophagitis: Swallowed topical corticosteroids—orodispersible budesonide or swallowed fluticasone formulations—coupled with PPI co-therapy and dietary elimination strategies (six-food, four-food or targeted approaches) per gastroenterology guidance; biologic therapy (dupilumab) has expanding evidence in selected refractory cases.
• Candida esophagitis: Oral fluconazole 200–400 mg/day for 14–21 days per IDSA guidance; topical nystatin alone is insufficient for esophageal disease but supports oral hygiene therapy.
• Herpes simplex esophagitis: Aciclovir 400 mg five times daily orally (or IV in severe disease) for 14–21 days; cytomegalovirus disease typically requires IV ganciclovir or valganciclovir under specialist guidance.
• Pill esophagitis: Stop or substitute the offending agent immediately, deliver remaining doses with at least 200 mL of water in the upright position, avoid bedtime dosing for bisphosphonates, and review formulary alternatives (e.g. IV bisphosphonates) with the prescriber.

Second-line / interventional alternatives

Endoscopic dilation manages strictures from chronic reflux or eosinophilic disease; anti-reflux surgery (typically laparoscopic fundoplication) or magnetic sphincter augmentation is considered for persistent disease despite optimised therapy or for patients intolerant of long-term medication; bariatric pathways are increasingly part of severe-reflux discussions in obesity. Endoscopic clip or band ligation manages associated bleeding lesions; significant benign ulceration may require repeated dilation series with dietary counselling.

Special populations

• Pregnancy: Lifestyle measures and alginates first; H2 blockers and selected PPIs (e.g. omeprazole) are commonly used when symptoms persist, but always defer prescribing decisions to obstetric/maternal-medicine teams.
• Immunosuppressed: Maintain a low threshold for endoscopy and broad antimicrobial coverage; coordinate with infectious diseases for HIV, transplant or oncology cohorts.
• Older adults: Review polypharmacy, calcium-channel blockers and anticholinergics that lower sphincter tone; balance bone-health risks of long-term PPIs with severity of disease and avoid escalation without documented review.
• Children and adolescents: Eosinophilic esophagitis often presents as feeding difficulty, vomiting or failure to thrive; pediatric gastroenterology pathways differ on dietary and biologic options.

This section bundles operational expectations bridging ward, ambulatory and pre-procedural interfaces.

• Observation cadence: Inpatients with active bleeding, suspected perforation or food impaction warrant continuous monitoring with vitals at minimum hourly until escalation pathways stabilise; uncomplicated outpatients use scheduled follow-up at 4–8 weeks after starting PPI therapy.
• PPI administration discipline: Document dose, timing and meal relationship; suboptimal pre-meal dosing is a common reason for “PPI failure” and should be corrected before escalating.
• Treatment failure triggers: Persistent symptoms after 8 weeks, recurrent food impaction, progressive dysphagia, weight loss or evolving anemia—each warrants gastroenterology referral and re-endoscopy rather than indefinite dose escalation.
• Drug interactions: Verify QT-prolonging combinations when prescribing fluconazole or macrolides with antiemetics, antipsychotics or methadone; PPIs affect clopidogrel activation pharmacology—coordinate cardiology input rather than autonomous switching.
• Antibiotic and antifungal stewardship: Confirm fungal/viral diagnostic samples before empirical agents in immunosuppressed cohorts; document rationale and end dates to avoid silent prolongation.
• Referral thresholds: Refractory symptoms despite optimised PPI, suspicion of eosinophilic disease, recurrent strictures, suspected Barrett’s esophagus or any alarm feature mandate gastroenterology involvement; multidisciplinary planning is essential before anti-reflux surgery.
• Procedure preparation: Verify fasting, anticoagulation and antiplatelet plans before endoscopy per institutional protocol; reconcile medications with pharmacy and document clearly during medication reconciliation.

• Esophageal stricture causing progressive dysphagia and food impaction.
• Barrett’s esophagus and adenocarcinoma risk in chronic erosive disease—surveillance discussions per gastroenterology pathways.
• Upper GI bleeding from erosive lesions or ulcers—anticipate transfusion thresholds in anticoagulated patients with hematemesis or melena.
• Esophageal perforation (rare but life-threatening), particularly post-instrumentation, severe Boerhaave-type events, or in the setting of caustic injury.
• Fibrosis, dysmotility and aspiration risk—predisposing to recurrent respiratory infections.
• Nutritional compromise, dehydration, early satiety and weight loss in advanced eosinophilic or stricturing disease.

Clinician-facing prevention focuses on durable risk modification and safe medication practice. Reinforce weight optimisation, smoking cessation, alcohol moderation, head-of-bed elevation, avoidance of late evening meals, and review of medications that lower sphincter tone. Counsel patients on inhaled corticosteroids about consistent mouth rinsing to reduce local Candida burden. For pill-induced disease, build the upright-water-30-minute rule into discharge teaching for every implicated agent, escalate to alternative formulations where mucosal injury has occurred, and document the patient’s understanding before transfer of care.

Reflux esophagitis usually heals on appropriate acid suppression within weeks; severe (LA C/D) disease has higher recurrence and Barrett’s risk and benefits from maintenance therapy and surveillance. Eosinophilic esophagitis is chronic and relapsing—patients require sustained pharmacologic and/or dietary therapy with periodic endoscopic reassessment. Infectious phenotypes resolve with appropriate antimicrobial therapy when host immunity stabilises; recurrence reflects incomplete control of underlying immunosuppression. Pill esophagitis typically heals quickly once the offending agent is removed, but stricture risk persists where ulceration was deep. Counsel patients on realistic timelines and the importance of follow-up scopes when staged disease, biopsy uncertainty or complication risk warrants it.

Bedside monitoring checklist

• Pain score, swallowing safety and oral-tolerance ladder (sips → free fluids → soft diet) reassessed at every shift, particularly after food impaction.
• Antimicrobial and PPI administration timing documented to the minute; loud handover when infusions or oral doses span shift change.
• Inspect the oropharynx for thrush in patients on inhaled or systemic steroids; reinforce mouth care after every steroid inhalation.
• Maintain head-of-bed elevation (Fowler’s position) for at-risk patients; capture intake and output trends if vomiting or oral intake limited.
• Establish reliable IV access with timely IV insertion when bleeding, sepsis or peri-procedural needs are anticipated.

Documentation & communication

Record longitudinal symptom trajectory with objective descriptors—pain location, swallowing safety, regurgitation timing—rather than “stable.” Document every counselling conversation about pill-administration technique, lifestyle modification and red-flag safety-netting. Capture allergies, prior endoscopic findings, and Barrett’s history where relevant; flag immunosuppression status prominently for cross-cover teams and pharmacy.

Activate emergency or critical-care pathways when:

• Patient cannot manage own saliva, drools or experiences acute total dysphagia—suggests fixed obstruction needing urgent endoscopy.
• Hematemesis, large-volume coffee-ground emesis, melena or hemodynamic instability.
• Sudden severe retrosternal or interscapular pain, subcutaneous emphysema or features of sepsis after vomiting or instrumentation—perforation pathway.
• Crushing chest pain with diaphoresis or arrhythmia—prioritise cardiac assessment in parallel.
• Immunosuppressed patient with fever, odynophagia and shock physiology—broad antimicrobial cover plus rapid escalation.

Escalate to senior nursing and medical leadership concurrently with pre-alert to receiving units; package transfer documentation with imaging summaries, antimicrobial administration times and allergy status.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of esophagitis recognition (reflux, eosinophilic, infective, pill, caustic), structured PPI / dietary / endoscopic care and the alarm-dysphagia / haematemesis / oesophageal-perforation / sepsis red flags.